Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells-Reference-Cited by-同舟云学术

Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells

Published:2023-03 Issue:3 Volume:31 Page:676-685
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Sasu Barbra J.,Opiteck Gregory J.,Gopalakrishnan Suhasni,Kaimal Vivek,Furmanak Tom,Huang David,Goswami Angshumala,He Ying,Chen Jiamin,Nguyen Anh,Balakumaran Arun,Shah Nirav N.,Hamadani Mehdi,Bone Kathleen M.,Prashad Sacha,Bowen Michael A.,Pertel Thomas,Embree Heather D.,Gidwani Shalini G.,Chang David,Moore Alison,Leonard Mark,Amado Rafael G.^ORCID

Funder

Incyte

Lilly Oncology

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference47 articles.

1. CAR T cell immunotherapy for human cancer;June;Science,2018

2. Chimeric antigen receptor therapy;June;N. Engl. J. Med.,2018

3. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia;Fraietta;Nat. Med.,2018

4. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells;Ghassemi;Cancer Immunol. Res.,2018

5. Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma;Graham;Leukemia,2021

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetically engineered hypoimmunogenic cell therapy;Nature Reviews Bioengineering;2024-07-29

2. Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review;Frontiers in Oncology;2024-06-07

3. Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells;Frontiers in Bioengineering and Biotechnology;2024-05-31

4. Allogeneic CAR T Cell Therapy for Cancer;Annual Review of Cancer Biology;2023-12-18

5. Unbiased assessment of genome integrity and purging of adverse outcomes at the target locus upon editing of CD4⁺ T‐cells for the treatment of Hyper IgM1;The EMBO Journal;2023-11-02